ABSTRACT
The molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae (KPC) has been largely investigated, but limited clinical information is available. A case-control study was performed to evaluate the risk factors for KPC bacteremia in hospitalized patients. Cases were patients with KPC bacteremia and controls were patients with non-KPC bacteremia. A total of 85 patients were included, 18 (21.2%) were KPC, and 67 (78.8%) were non-KPC (40 [59.7%] of them were extended-spectrum beta-lactamase producers). All KPC isolates were type 2 producers. These isolates belong to five distinct clones. Multivariate analysis showed that age (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02 - 1.11; p = 0.004), presence of mechanical ventilation (OR, 11.1; 95% CI, 1.92 - 63.3; p = 0.007) and fluoroquinolone exposure during hospitalization (OR, 28.9; 95% CI, 1.85 - 454.6; p = 0.02) were independent risk factors for KPC in patients with K. pneumoniae bacteremia. Factors associated with severity of illness, such as age and mechanical ventilation, seem to be the main risks factors for KPC. Fluoroquinolones use might be a risk factor for KPC bacteremia. Further investigations on risk factors for KPC are warranted.
Subject(s)
Female , Humans , Male , Middle Aged , Bacteremia/microbiology , Bacterial Proteins/metabolism , Cross Infection/microbiology , Klebsiella Infections/microbiology , Klebsiella pneumoniae/enzymology , beta-Lactamases/metabolism , Bacteremia/diagnosis , Cross Infection/diagnosis , Epidemiologic Methods , Klebsiella Infections/diagnosis , Klebsiella Infections/epidemiologyABSTRACT
The molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae (KPC) has been largely investigated, but limited clinical information is available. A case-control study was performed to evaluate the risk factors for KPC bacteremia in hospitalized patients. Cases were patients with KPC bacteremia and controls were patients with non-KPC bacteremia. A total of 85 patients were included, 18 (21.2%) were KPC, and 67 (78.8%) were non-KPC (40 [59.7%] of them were extended-spectrum beta-lactamase producers). All KPC isolates were type 2 producers. These isolates belong to five distinct clones. Multivariate analysis showed that age (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02 - 1.11; p = 0.004), presence of mechanical ventilation (OR, 11.1; 95% CI, 1.92 - 63.3; p = 0.007) and fluoroquinolone exposure during hospitalization (OR, 28.9; 95% CI, 1.85 - 454.6; p = 0.02) were independent risk factors for KPC in patients with K. pneumoniae bacteremia. Factors associated with severity of illness, such as age and mechanical ventilation, seem to be the main risks factors for KPC. Fluoroquinolones use might be a risk factor for KPC bacteremia. Further investigations on risk factors for KPC are warranted.
Subject(s)
Bacteremia/microbiology , Bacterial Proteins/metabolism , Cross Infection/microbiology , Klebsiella Infections/microbiology , Klebsiella pneumoniae/enzymology , beta-Lactamases/metabolism , Bacteremia/diagnosis , Cross Infection/diagnosis , Epidemiologic Methods , Female , Humans , Klebsiella Infections/diagnosis , Klebsiella Infections/epidemiology , Male , Middle AgedABSTRACT
Background: Extended spectrum β-lactamase (ESBL)-producing bacteria have become recognized as a problem in South America. The aim of this study was to evaluate risk factors and mortality rate in bacteremia caused by ESBL-producing Klebsiella pneumoniae in a Brazilian hospital. Methods: A three-year retrospective cohort study with 104 cases of K. pneumoniae bacteremia (61 ESBL and 43 non-ESBL). Several clinical and laboratory variables were evaluated. The outcome of interest was 30-day mortality. The adequate treatment was evaluated according to antibiotic susceptibility. Results: Multivariable analysis showed that central venous catheter and mechanical ventilation were independent risk factors for ESBL. The duration of hospitalization before the bacteremia was not a risk factor. Mortality was similar in ESBL and non-ESBL and inadequate therapy was not shown to be a risk factor. Conclusion: ESBL-producing Klebsiella bacteremia can occur early, suggesting that a carbapenem should be included in the initial empirical therapy for bacteremia in patients under mechanical ventilation and/or central venous catheter in our institution.
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Bacteremia/mortality , Cross Infection/mortality , Klebsiella Infections/mortality , Klebsiella pneumoniae/enzymology , beta-Lactamases/metabolism , Bacteremia/microbiology , Cohort Studies , Cross Infection/microbiology , Klebsiella Infections/microbiology , Retrospective Studies , Risk FactorsSubject(s)
Acinetobacter Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Carbapenems/therapeutic use , Cross Infection/drug therapy , Polymyxins/therapeutic use , beta-Lactam Resistance , Acinetobacter/drug effects , Acinetobacter/isolation & purification , Acinetobacter Infections/microbiology , Acinetobacter Infections/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/microbiology , Bacteremia/mortality , Brazil , Child , Cross Infection/microbiology , Cross Infection/mortality , Female , Humans , Male , Middle Aged , Survival Analysis , Young AdultABSTRACT
BACKGROUND: Extended spectrum ß-lactamase (ESBL)-producing bacteria have become recognized as a problem in South America. The aim of this study was to evaluate risk factors and mortality rate in bacteremia caused by ESBL-producing Klebsiella pneumoniae in a Brazilian hospital. METHODS: A three-year retrospective cohort study with 104 cases of K. pneumoniae bacteremia (61 ESBL and 43 non-ESBL). Several clinical and laboratory variables were evaluated. The outcome of interest was 30-day mortality. The adequate treatment was evaluated according to antibiotic susceptibility. RESULTS: Multivariable analysis showed that central venous catheter and mechanical ventilation were independent risk factors for ESBL. The duration of hospitalization before the bacteremia was not a risk factor. Mortality was similar in ESBL and non-ESBL and inadequate therapy was not shown to be a risk factor. CONCLUSION: ESBL-producing Klebsiella bacteremia can occur early, suggesting that a carbapenem should be included in the initial empirical therapy for bacteremia in patients under mechanical ventilation and/or central venous catheter in our institution.
Subject(s)
Bacteremia/mortality , Cross Infection/mortality , Klebsiella Infections/mortality , Klebsiella pneumoniae/enzymology , beta-Lactamases/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/microbiology , Child , Cohort Studies , Cross Infection/microbiology , Female , Humans , Klebsiella Infections/microbiology , Male , Middle Aged , Retrospective Studies , Risk Factors , Young AdultABSTRACT
BACKGROUND: The mortality rate due to Acinetobacter baumannii nosocomial meningitis (ANM) is high. OBJECTIVE: The aim of this study was to evaluate the factors that have influence over the outcomes in ANM patients. METHODS: A retrospective analysis of 22 cases of ANM was conducted in a hospital with high incidence of multidrug resistance. RESULTS: The mean age of patients was 43 years (21 to 91) and 54.5 percent were male. All ANM cases occurred within 60 days of admission and the mean duration of illness was of 18.2 days. All cases were associated with previous neurosurgical procedures: elective surgery (27.2 percent), external shunt (54.4 percent) and emergency surgery due to trauma (18.1 percent). Imipenem resistance was observed in 40.9 percent of cases, but ampicillin/sulbactam resistance was lower (27.2 percent). The mortality rate of ANM patients was of 72.7 percent. The only risk factor associated with mortality was inappropriate therapy within five days after CSF collection. All patients who survived the meningitis episode had received appropriate therapy, in contrast to only 69.2 percent of those who did not survive (OR = 5.15; IC = 0.45-54.01). CONCLUSIONS: The high mortality rate observed in our study suggests the need for aggressive empirical treatment with addition of drugs, including intrathecal therapy, where multi-resistant A. baumannii is endemic.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Acinetobacter baumannii , Acinetobacter Infections/mortality , Cross Infection/mortality , Meningitis, Bacterial/mortality , Acinetobacter Infections/drug therapy , Acinetobacter Infections/microbiology , Brazil , Cross Infection/drug therapy , Cross Infection/microbiology , Epidemiologic Methods , Meningitis, Bacterial/drug therapy , Meningitis, Bacterial/microbiologyABSTRACT
BACKGROUND: The mortality rate due to Acinetobacter baumannii nosocomial meningitis (ANM) is high. OBJECTIVE: The aim of this study was to evaluate the factors that have influence over the outcomes in ANM patients. METHODS: A retrospective analysis of 22 cases of ANM was conducted in a hospital with high incidence of multidrug resistance. RESULTS: The mean age of patients was 43 years (21 to 91) and 54.5% were male. All ANM cases occurred within 60 days of admission and the mean duration of illness was of 18.2 days. All cases were associated with previous neurosurgical procedures: elective surgery (27.2%), external shunt (54.4%) and emergency surgery due to trauma (18.1%). Imipenem resistance was observed in 40.9% of cases, but ampicillin/sulbactam resistance was lower (27.2%). The mortality rate of ANM patients was of 72.7%. The only risk factor associated with mortality was inappropriate therapy within five days after CSF collection. All patients who survived the meningitis episode had received appropriate therapy, in contrast to only 69.2% of those who did not survive (OR = 5.15; IC = 0.45-54.01). CONCLUSIONS: The high mortality rate observed in our study suggests the need for aggressive empirical treatment with addition of drugs, including intrathecal therapy, where multi-resistant A. baumannii is endemic.
Subject(s)
Acinetobacter Infections/mortality , Acinetobacter baumannii , Cross Infection/mortality , Meningitis, Bacterial/mortality , Acinetobacter Infections/drug therapy , Acinetobacter Infections/microbiology , Adult , Aged , Aged, 80 and over , Brazil , Cross Infection/drug therapy , Cross Infection/microbiology , Epidemiologic Methods , Female , Humans , Male , Meningitis, Bacterial/drug therapy , Meningitis, Bacterial/microbiology , Middle Aged , Young AdultABSTRACT
This is the first case reported of central venous catheter-related fungemia due to C. neoformans. A patient with chronic renal failure developed a fungemia during the treatment of a dialysis-associated bacteremia. Cryptococcus neoformans grew in the catheter tip and blood culture. We addressed questions about this catheter-related fungemia.
Subject(s)
Female , Humans , Middle Aged , Catheter-Related Infections/microbiology , Catheterization, Central Venous/adverse effects , Cryptococcosis/microbiology , Cryptococcus neoformans/isolation & purification , Fungemia/microbiology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Catheter-Related Infections/diagnosis , Catheter-Related Infections/drug therapy , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Fatal Outcome , Fungemia/diagnosis , Fungemia/drug therapy , Kidney Failure, Chronic/therapy , Renal Dialysis/adverse effectsSubject(s)
Disease Outbreaks , Laparoscopy/adverse effects , Mycobacterium Infections, Nontuberculous/epidemiology , Nontuberculous Mycobacteria/isolation & purification , Population Surveillance/methods , Surgical Wound Infection/epidemiology , Brazil/epidemiology , Hospitals, University , Humans , Mycobacterium Infections, Nontuberculous/microbiology , Nontuberculous Mycobacteria/classification , Patient Discharge , Postoperative Care , Surgical Wound Infection/microbiology , TelephoneABSTRACT
This is the first case reported of central venous catheter-related fungemia due to C. neoformans. A patient with chronic renal failure developed a fungemia during the treatment of a dialysis-associated bacteremia. Cryptococcus neoformans grew in the catheter tip and blood culture. We addressed questions about this catheter-related fungemia.
Subject(s)
Catheter-Related Infections/microbiology , Catheterization, Central Venous/adverse effects , Cryptococcosis/microbiology , Cryptococcus neoformans/isolation & purification , Fungemia/microbiology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Catheter-Related Infections/diagnosis , Catheter-Related Infections/drug therapy , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Fatal Outcome , Female , Fungemia/diagnosis , Fungemia/drug therapy , Humans , Kidney Failure, Chronic/therapy , Middle Aged , Renal Dialysis/adverse effectsABSTRACT
Carbapenem-resistant Acinetobacter baumannii isolates were obtained from eight patients in two hospitals in Curitiba, Brazil. The isolates were multiresistant, belonged to a single strain, and produced the OXA-23 carbapenemase. Treatment options were limited, although the isolates were susceptible to polymyxin B in vitro. The strain contributed to the deaths of five patients.
Subject(s)
Acinetobacter Infections/epidemiology , Acinetobacter baumannii/drug effects , Carbapenems/pharmacology , Disease Outbreaks , Drug Resistance, Bacterial , beta-Lactamases/metabolism , Acinetobacter Infections/microbiology , Acinetobacter baumannii/enzymology , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , Hospitals, Teaching , Humans , Microbial Sensitivity Tests , Middle AgedSubject(s)
Humans , Male , Female , Enzyme-Linked Immunosorbent Assay/statistics & numerical data , Leprosy/epidemiology , Mycobacterium leprae/immunology , Immunologic Tests/methods , Enzyme-Linked Immunosorbent Assay , Enzyme-Linked Immunosorbent Assay/statistics & numerical data , Leprosy/diagnosis , Leprosy/therapy , Immunologic Tests/methods , Immunologic TestsABSTRACT
O estudo da tendência da Hanseniase no Brasil, fornece elementos suficientes para supor que a endemia hansénica encontra-se em expansäo. A estratégia atual para o controle baseia-se na detecçäo precoce e tratamento eficaz da doença. Através de uma revisäo bibliográfica atualizada sobre a Hanseníase observamos o emprego da prova de ELISA (Prova Imunoenzimática) frente a um antígeno espécie-específico do M. leprae para múltiplos propósitos, sendo no presente estudo aplicado para avaliar a resposta imune humoral de 7 pacientes hansenianos bacilíferos näo tratados e 24 pacientes hansenianos tratados sistematicamente. Sendo entäo, observado pelo emprego desta prova, diferenças significativas nos níveis e anticorpos específicos ao M. leprae. Outros ensaios laboratoriais foram executados como a Intradermoreaçäo de Mitsuda, índice Baciloscópico e na tentativa de definir uma prova laboratorial com sensibilidade e especificidade equivalente à prova de ELISA (frente ao Glicolipídio Fenolico i de M. leprae) procedemos a IDRS frente ao bacilo de Hansen inativado, verificando-se entäo, uma baixa especificidade na prova. Correlacionou-se também os níveis de anticorpos com resultados baciloscópicos constatando alta anticorpogênese nos casos sabiamente bacilíferos. Porém nos casos de pacientes näo bacilíferos (tratados), foi observada uma média de frequência de anticorpos inferior áquela obtida no grupo de pacientes näo tratados. Estes resultados sugerm que a quantificaçäo segura e específica dos níveis de anticorpos em hansenianos é um elemento de aplicaçäo na monitorizaçäo da terapêutica adotada. Quatro dados foram levantados e discutidos porém, näo se mostraram conclusivos
